1. Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., & Cipolla, C. M. (2016). Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA: A Cancer Journal for Clinicians, 66(4), 309–325.
2. Porter, C., Azam, T. U., Mohananey, D., Kumar, R., Chu, J., Lenihan, D., Dent, S., Ganatra, S., Beasley, G. S., & Okwuosa, T. (2022). Permissive cardiotoxicity: The clinical crucible of cardio-oncology. JACC: CardioOncology, 4(3), 302–312.
3. Skitch, A., Mital, S., Mertens, L., Liu, P., Kantor, P., Grosse-Wortmann, L., Manlhiot, C., Greenberg, M., & Nathan, P. C. (2017). Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study. BMC Cancer, 17(1), 519.
4. Quagliariello, V., De Laurentiis, M., Cocco, S., Rea, G., Bonelli, A., Caronna, A., Lombari, M. C., Conforti, G., Berretta, M., Botti, G., & Maurea, N. (2020). NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells. International Journal of Molecular Sciences, 21(20), 7802.
5. Quagliariello, V., Paccone, A., Iovine, M., Cavalcanti, E., Berretta, M., Maurea, C., Canale, M.L., Maurea, N. (2021). Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: Possible implications in cancer patients with COVID-19. European Review for Medical & Pharmacological Sciences. 25(21).